Proton beam therapy for gliomas: a multicenter prospective registry study from all proton beam facilities in Japan

• Published in: Journal of radiation research 2023-06, Vol.64 (Supplement_1), p.i59-i68
• Main Authors: Mori, Takashi, Mizumoto, Masashi, Maebayashi, Katsuya, Nishioka, Kentaro, Arakawa, Yoshiki, Kurozumi, Kazuhiko, Yasuda, Koichi, Sumiya, Taisuke, Tamamura, Hiroyasu, Sato, Yoshitaka, Waki, Takahiro, Takagi, Masaru, Takada, Yu, Okimoto, Tomoaki, Murakami, Masao, Kikuchi, Yasuhiro, Okada, Kazufumi, Ito, Yoichi M, Akimoto, Tetsuo, Aoyama, Hidefumi
• Format: Article
• Language: English
• Subjects: Not Selected
• ISSN: 0449-3060; 1349-9157
• DOI: 10.1093/jrr/rrac103

We reviewed the outcomes of glioma patients enrolled in a prospective observational registry study of proton beam therapy (PBT) in Japan. The inclusion criteria were glioma patients registered in the Electronic Data Capture system, the Proton-net, between May 2016 and July 2019. Data on patient characteristics, treatments, late adverse events, survival status, recurrence and secondary tumors were extracted and statistically analyzed. The primary endpoint was the overall survival (OS) rate, and the secondary endpoints were the progression-free survival (PFS) rate and cumulative local recurrence rate (cLRR). Of the 65 primary brain tumor patients registered, 29 glioma patients from eight of 19 PBT facilities met the inclusion criteria. There were 19 glioblastoma patients, eight of other malignant gliomas, and two of low-grade gliomas. For glioblastomas, with a median follow-up period of 16 months, the median survival time was 21.2 months and the OS at 1, 2, 3 and 4 years were 77.4%, 44.9%, 23.9% and 23.9%, respectively. The median PFS period was 10.1 months, the 1, 2, 3 and 4-year PFS were 32.4%, 19.4%, 9.7% and 9.7%, respectively. The 1, 2, 3 and 4-year cLRR were 56.1%, 68.8%, 78.4 and 78.4%, respectively. Grade 3 brain necrosis was observed in two patients. No secondary tumor was observed. This is the first report on the current status of PBT for gliomas in Japan. For glioblastomas, the outcomes of PBT are estimated to be equivalent to historical data of photon therapy. The results of a prospective comparative evaluation of PBT and photon therapy are awaited.